Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures

Journal of Bone and Mineral Research

Volumn 19, Issue 10, 2004, Pages 1706-1711

  Ohyama, Yoshio ^a,b   Nemoto, Hiroyuki ^a   Rittling, Susan ^c   Tsuji, Kunikazu ^a   Amagasa, Teruo ^a   Denhardt, David T ^c   Nifuji, Akira ^a   Noda, Masaki ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone   (Japan)

^c State University of New Jersey   (United States)

Author keywords

Bone marrow ablation; Melanoma; Osteoclast; Osteopontin; Tumor invasion

Indexed keywords

OSTEOPONTIN; ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ISOENZYME; SIALOGLYCOPROTEIN; SPP1 PROTEIN, MOUSE; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER INHIBITION; CELL CULTURE; COCULTURE; CONTROLLED STUDY; CORTICAL BONE; MELANOMA CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PROTEIN DEFICIENCY; STATISTICAL SIGNIFICANCE; TUMOR CELL; WILD TYPE; ANIMAL; BONE MARROW CELL; BONE REGENERATION; BONE TUMOR; CELL DIVISION; EXPERIMENTAL MELANOMA; FEMALE; FEMUR; MALE; METABOLISM; METASTASIS; MOUSE MUTANT; OSTEOCLAST; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACID PHOSPHATASE; ANIMALS; BONE MARROW; BONE MARROW CELLS; BONE NEOPLASMS; BONE REGENERATION; CELL DIVISION; COCULTURE TECHNIQUES; FEMALE; FEMUR; ISOENZYMES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; OSTEOCLASTS; OSTEOPONTIN; SIALOGLYCOPROTEINS; TUMOR CELLS, CULTURED;

EID: 18244406113     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2004.19.10.1706     Document Type: Article

References (24)

1. Hiraga T, Nakajima T, Ozawa H 1995 Bone resorption induced by a metastatic human melanoma cell line. Bone 16:349-36.
2. Rodan GA 2003 The development and function of the skeleton and bone metastases. Cancer 97(Suppl 3):726-732.
3. Guise TA, Mundy GR 1998 Cancer and bone. Endocr Rev 19:18-54.
4. Denhardt DT, Noda M 1998 Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 31:92-102.
5. Senger DR, Perruzzi CA, Papadopoulos A 1989 Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299.
6. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR, Papadopoulos A 1992 Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Mol Biol Cell 3:1169-1180.
7. Denhardt DT, Chambers AF 1994 Overcoming obstacles to metastasis - defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 56:48-51.
8. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M 2001 Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 16:652-659.
9. Guise TA 1997 Parathyroid hormone-related protein and bone metastases. Cancer 80(Suppl 8):1572-1580.
10. Ono K, Akatsu T, Murakami T, Wada S, Nishikawa M, Kugai N, Yamamoto M, Matsuura N, Nagata N 1998 Mouse mammary carcinoma cell line (BALB/c-MC) stimulates osteoclast formation from mouse bone marrow cells through cell-to-cell contact. Bone 23:27-32.
11. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
13. Hofbauer LC, Neubauer A, Heufelder AE 2001 Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460-470.
14. Kitazawa S, Kitazawa R 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198:228-236.
15. Ohshiba T, Miyaura C, Inada M, Ito A 2003 Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer 88:1318-1326.
16. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K 2001 Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637-1644.
17. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
18. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT 1998 Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13:1101-1111.
19. Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T 2000 Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632-637.
20. Rak J, Kerbel RS 2001 Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 333:267-283.
21. Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S, Rittling SR 2003 Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 20:77-84.
22. Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe Y, Takahashi K, Fukuchi Y, Saijo N, Nishio K 2002 Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98:707-712.
23. Philip S, Bulbule A, Kundu GC 2001 Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276:44926-44935.
24. Philip S, Kundu GC 2003 Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I-kappa B-alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278:14487-14497.